FDA Grants Orphan Drug Designation to Evorpacept for AML
ALX Oncology Holdings announced that the U.S. Food and Drug Administration had granted orphan drug designation to Evorpacept, a next-generation CD47 blocker, for treating patients with acute myeloid leukemia (AML).
Acute Myeloid Leukemia (AML) is an aggressive blood-cell cancer that can rapidly progress and lead to death if not treated instantly. Acute myeloid leukemia is the most common type of acute leukemia in adults, with an estimated number of 20,000 new cases and 11,500 deaths from the disease in the United States in 2022.
Due to the advanced age and comorbidities at the time of diagnosis, m...
